The findings indicated a significant improvement in the activity, proliferation, and invasion ability of COAD, suggesting that LRRC59 may serve as an early prognostic biomarker and a therapeutic target in COAD. This evidence concerns the gene LRRC59 and colon adenocarcinoma.